Cronos GroupCRON +3.31%86 EBITDA Margin % is 5.03% as of Mar. 2026. GuruFocus rates CRON with a GF Score™ of 86/100 and a GF Value™ of $3.45 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Cronos Group ranks worse than 76.75% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Cronos Group's EBITDA for the
three
months ended in Mar. 2026 was $2.3 Mil. Cronos Group's Revenue for the
three
months ended in Mar. 2026 was $45.2 Mil. Therefore, Cronos Group's EBITDA margin for the quarter that ended in Mar. 2026 was 5.03%.
Cronos Group (NAS:CRON) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Cronos Group EBITDA Margin % Related Terms
Cronos Group EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Cronos Group's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cronos Group's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cronos Group EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cronos Group's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Cronos Group's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cronos Group (CRON) has a EBITDA Margin % of 5.03% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cronos Group and its competitors. According to the industry distribution chart, Cronos Group ranks #733 out of 955 companies in the Drug Manufacturers industry, placing it in the top 76.8%.
Is Cronos Group's EBITDA Margin % too high?
Cronos Group's current EBITDA Margin % is 5.03%. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Cronos Group's value of 5.03% is 59.6% below this industry median. Based on the distribution chart, Cronos Group ranks #733 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cronos Group has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cronos Group's EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cronos Group ranks #733 out of 955 companies for EBITDA Margin %. This places Cronos Group in the lower half of its industry. The industry median EBITDA Margin % is 12.44. Cronos Group's value of 5.03% is 59.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cronos Group's current EBITDA Margin % of 5.03% is 59.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Cronos Group and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cronos Group's current EBITDA Margin % is 5.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cronos Group stock overvalued right now?
Based on GuruFocus' analysis, Cronos Group (CRON) is currently considered Modestly Undervalued. The stock's GF Value™ is $3.45, compared to a current price of $2.82 — trading 18.3% below its estimated fair value. The current EBITDA Margin % is 5.03% and 59.6% below the Drug Manufacturers industry median of 12.44. Cronos Group's overall GF Score™ is 86/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Cronos Group (CRON), the current EBITDA Margin % is 5.03% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cronos Group (CRON) Overvalued in 2026?
Based on GuruFocus' analysis, Cronos Group stock appears to be undervalued.
The current stock price of $2.82 is trading 18.3% below its estimated GF Value™ of $3.45.
GuruFocus considers Cronos Group to be Modestly Undervalued.
Key valuation signals for CRON:
EBITDA Margin %: 5.03%
GF Value™: $3.45 vs. price of $2.82 (18.3% below fair value)
Industry Position: 59.6% below the Drug Manufacturers median (#733 of 955)
No single metric tells the full story. See the CRON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cronos Group Inc is a cannabinoid company committed to building disruptive intellectual property by advancing cannabis research, technology, and product development. With a passion for responsibly elevating the consumer experience, the company is building an iconic brand portfolio. Its diverse international brand portfolio includes Spinach, PEACE NATURALS, LIT, and Lord Jones. The company operates in Canada, Israel, and other countries, with the majority of its revenue generated from Canada.
86GF Score
Get the complete analysis for CRON
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CRON has been successfully added to your 
